The compensatory anti-inflammatory cytokine interleukin 10 response in pediatric sepsis-induced multiple organ failure

Chest

Volumn 113, Issue 6, 1998, Pages 1625-1631

  Doughty, Lesley ^a   Carcillo, Joseph A ^b,c   Kaplan, Sandra ^b   Janosky, Janine ^b  

^a WILFORD HALL MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

Author keywords

Children; Compensatory anti inflammatory response syndrome; Interleukin 10; Interleukin 6; Multiple organ failure; Nitric oxide; Sepsis

Indexed keywords

INTERLEUKIN 10;

ADOLESCENT; ADULT; ARTICLE; BLOOD CULTURE; CHILD; HUMAN; IMMUNE RESPONSE; INFANT; KIDNEY FAILURE; LIVER FAILURE; LUNG INSUFFICIENCY; MAJOR CLINICAL STUDY; MULTIPLE ORGAN FAILURE; PRIORITY JOURNAL; SEPSIS;

EID: 0031801904     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.113.6.1625     Document Type: Article

References (31)

1. Goldman M, Thierry V. Interleukin-10 and its implications for immunopathology. Adv Nephrol 1995; 24:79-90
2. de Waal Malefyt R, Abrams J, Bennett B, et al. Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med 1991; 174:1209-20
3. de Waal Malefyt R, Yssel H, Roncarolo MG, et al. Interleukin-10 [review]. Curr Opin Immunol 1992; 4:314-20
4. Gazzinelli RT, Oswald IP, James SL, et al. IL-10 inhibits parasite killing and nitrogen oxide production by IFN-γ-activated macrophages. J Immunol 1992; 148:1792-96
5. de Waal Malefyt R, Haanen J, Spits H, et al. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J Exp Med 1991; 174:915-24
6. Willems F, Marchant A, Delville JP, et al. Interleukin-10 inhibits B7 and intercellular adhesion molecule-1 expression on human monocytes. Eur J Immunol 1994; 24:1007-09
7. Kasama T, Stricter RM, Lukacs NW, et al. Regulation of neutrophil-derived chemokine expression by IL-10. J Immunol 1994; 152:3559-69
8. Rousset F, Garcia E, Defrance T, et al. Interleukin-10 is a potent growth and differentiation factor for activated human B lymphocytes. Proc Natl Acad Sci USA 1992; 89:1890-93
9. Gerard C, Bruyns C, Marchant A, et al. Interleukin 10 reduces the release of tumor necrosis factor and prevents lethality in experimental endotoxemia. J Exp Med 1993; 177:547-50
10. Howard M, Muchamuel T, Andrade S, et al. Interleukin 10 protects mice from lethal endotoxemia. J Exp Med 1993; 177:1205-08
11. van der Poll T, Marchant A, Buurman WA, et al. Endogenous IL-10 protects mice from death during septic peritonitis. J Immunol 1995; 155:5397-5401
12. Ishida H, Hastings R, Thompson-Snipes L, et al. Modified immunological status of anti-IL-10 treated mice. Cell Immunol 1993; 148:371-84
13. Kuhn R, Lohler J, Rennick D, et al. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 1993; 75:263-74
14. Romani L, Puccetti P, Mencacci A, et al. Neutralization of IL-10 up-regulates nitric oxide production and protects susceptible mice from challenge with Candida albicans. J Immunol 1994; 152:3514-21
15. Marchant A, Deviere J, Byl B, et al. Interleukin-10 production during septicaemia. Lancet 1994; 343:707-08
16. Derkx B, Marchant A, Goldman M, et al. High levels of interleukin-10 during the initial phase of fulminant meningococcal septic shock. J Infect Dis 1995; 171:229-32
17. Marchant A, Alegre ML, Hakim A, et al. Clinical and biological significance of interleukin-10 plasma levels in patients with septic shock. J Clin Immunol 1995; 15:266-73
18. Gomez-Jimenez J, Martin MC, Sauri R, et al. Interleukin-10 and the monocyte/macrophage-induced inflammatory response in septic shock. J Infect Dis 1995; 171:472-75
19. Sherry RM, Cue JI, Goddard JK, et al. Interleukin-10 is associated with the development of sepsis in trauma patients. J Trauma 1996; 40:613-17
20. Doughty LA, Kaplan SS, Carcillo JA. Inflammatory cytokine and nitric oxide responses in pediatric sepsis and organ failure. Crit Care Med 1996; 24:1137-43
21. Brandtzaeg P, Osnes L, Ovstebo R, et al. Net inflammatory capacity for human septic shock plasma evaluated by a monocyte-based target cell assay: identification of interleukin-10 as a major functional deactivates of human monocytes. J Exp Med 1996; 184:51-60
22. Chernoff AE, Granowitz EV, Shapiro L, et al. A randomized, controlled trial of IL-10 in humans: inhibition of inflammatory cytokine production and immune responses. J Immunol 1995; 154:5492-99
23. Huhn RD, Radwanski E, O'Connell SM, et al. Pharmacokinetics and immunomodulatory properties of intravenously administered recombinant human interleukin-10 in healthy volunteers. Blood 1996; 87:699-705
24. Bone RC. Immunologic dissonance: a continuing evolution in our understanding of the systemic inflammatory response syndrome and the multiple organ dysfunction syndrome. Ann Intern Med 1996; 125:690-691
25. Bone RC, Fischer CJ Jr, Clemmer TP, et al. Sepsis syndrome: a valid clinical entity. Crit Care Med 1989; 17:389-93
26. Wilkinson JD, Pollack MM, Ruttimann UE, et al. Outcome of pediatric patients with multiple organ system failure. Crit Care Med 1986; 14:271-74
27. Proulx F, Fayon M, Farrell CA, et al. Epidemiology of sepsis and multiple organ dysfunction syndrome in children. Chest 1996; 109:1033-37
28. Arai T, Hiromatsu K, Kobayashi N, et al. IL-10 is involved in the protective effect of dibutyryl cyclic adenosine monophosphate on endotoxin-induced inflammatory liver injury. J Immunol 1995; 155:5743-49
29. Kato T, Murata A, Ishida H, et al. Interleukin 10 reduces mortality from severe peritonitis in mice. Antimicrob Agents Chemother 1995; 39:1336-40
30. Kox WJ, Bone RC, Krausch D, et al. Interferon gamma-1b in treatment of compensatory anti-inflammatory response syndrome a new approach: proof of principle. Arch Intern Med 1997; 157:389-93
31. Baue AE. Multiple organ failure, multiple organ dysfunction syndrome, and the systemic inflammatory response syndrome - where do we stand? Shock 1994; 2:385-97